CORRECTING and REPLACING Zetagen Therapeutics Presents Phase 2a Results at ASCO for Investigational ZetaMetTM (Zeta BC 003) in Metastatic Breast Cancer Patients with Lytic Bone Lesions

AUSTIN, Texas--(BUSINESS WIRE)--The company is issuing the following corrected version of the release originally distributed on June 9, 2026. In that release, we incorrectly stated that the Phase 2 study reported no treatment‐emergent adverse events. The correct statement is that the study reported no treatment‐related adverse events. No other data from the study are affected by this correction. Zetagen regrets the error and is issuing this clarification to ensure accurate communication. The up